◆ 会议时间：2023年10月25-27日
◆ 会议地点：意大利 佛罗伦萨

◆ 会议简介：

2023年第42届欧洲肿瘤外科学会(ESSO)年会将于2023年10月25-27日在意大利佛罗伦萨举行。ESSO年会将为肿瘤和肿瘤外科学术团体提供一个科学的环境和平台，包括普通外科医生、不同专业的外科肿瘤学家、学生、培训中的外科医生、住院医师、专科护士以及所有参与管理癌症患者的医护人员。ESSO大会将提供卓越的教育和交流机会，通过全体讲座、专家会议、辩论、科学研讨会和海报会议等形式，展示外科研究、患者管理和实践、肿瘤外科学标准、关键指南宣等方面的最新进展，全面地认识管理实体肿瘤的最新技术，以便与会的代表们可以带着改变实践的见解返回他们的机构，造福于全欧洲乃至全世界的癌症患者。未经许可禁止复制摘录转载本站任何内容-领域国际医学会议网(lingyuint.com)

欧洲肿瘤外科学会(ESSO)成立于1981年，宗旨是支持其成员通过推动肿瘤外科的科学和实践，来改善对患者的诊疗护理。ESSO每年组织欧洲最大的肿瘤外科学术大会。

ESSO 2023 - 42nd Congress of the European Society of Surgical Oncology
Date: 25-27 October 2023
Location: Florence, Italy

摘要征文投稿：

Abstract submission deadline： Tuesday, 30 May 2023

点此提交摘要>>>Submit Abstract>>>

ABSTRACT TOPICS

• BREAST CANCER
• COLORECTAL & ANAL CANCER
• HEAD & NECK AND THYROID CANCER
• HEPATOBILIARY AND PANCREATIC CANCER
• MELANOMA
• SARCOMA
• OESOPHAGEAL AND GASTRIC CANCER
• PERITONEAL SURFACE MALIGNANCIES
• RARE TUMOURS AND TRANSVERSAL TOPICS
• SURGICAL TRIAL PROPOSALS
• Research projects in the following categories will be considered:
  • Proposals for randomized controlled trials (RCTs)
  • Proposals for non-randomized studies
  • Proposals adapted for the setting of an LMIC (Low- and Middle-lncome countries)The research proposal must be in the advanced stage of development, but not yet active or recruiting patients.

ABSTRACT FORMAT

The abstract must be submitted in good English. The Scientific Committee reserves the right to reject abstracts presented in poor English or request an immediate revision by the presenting author.

No more than 20 authors can be listed. E-mail address, institutional affiliation, city, and country must be filled in. For cooperative study groups, the group’s name should be used instead of individual institutional affiliations or include the group’s name in the abstract’s title.

The title of the abstract should be concise and accurately describe the study undertaken. Do not use non-standard abbreviations and commercial names (generic names only).

Abstracts should be structured to include the following sections:

Proffered Papers

• Background: introductory sentence specifying the purpose of the study
• Material and methods: a brief description of relevant experimental procedures
• Results: summary of the results of the investigation
• Conclusions: a statement of the main conclusions

Surgical Trial Proposals

• Background – clearly state the following: Research question, background, objectives, preliminary data (if available), potential clinical impact
• Methods – clearly describe your research endpoints, study design, analysis plan, sample size, patient population, duration of the study
• Feasibility – Source of funding, target countries

The abstract submission system will not accept abstracts that exceed 2900 characters (including the body of the abstract, spaces and 1 table).

Only one data table is permitted in the body of the abstract. Illustrations and figures are not allowed and will be deleted if submitted.

Abbreviations may be used if standard or if spelt out and defined at the first use. Compounds should be mentioned with the generic name, in lower cases. Commercial names are admitted in the text, with an ®, and if in brackets following the generic name, i.e., “generic (Commercial ®)”.

ABSTRACT SELECTION PROCESS

Abstracts submitted for presentation at the ESSO 42 Congress will be reviewed by a panel of experts in the field of the subject and will be judged solely on the data submitted. The final decision on the presentation format of all selected abstracts lies at the sole discretion of the Scientific Committee.

The following presentation formats are applicable for the ESSO 42 Congress:

• Oral presentation = abstract is selected for oral presentation in the scientific programme.
• Poster presentation = abstract will be displayed as a poster on the electronic screens at the venue and will be accessible throughout the whole duration of the congress.
• Poster in Spotlight = abstract will be displayed as a poster on the electronic screens + presented as a short oral presentation in the Posters in Spotlight Session.
• Surgical Trial Protocol = protocol concept that will be selected for presentation in the transversal session: “Dragon´s Den: Clinical Research in surgical oncology” supported by the Anticancer Fund (ACF). During this session, 3 selected authors will have the opportunity to pitch their surgical trial proposal to a panel of experts. The best proposal will be rewarded with a prize of 500 EUR to further develop their protocol. The Anticancer Fund will also support trial presenters’ expenses as per ESSO conditions. Please note that only new research projects will be considered. On-going research will not be considered. The research proposal must be in the advanced stage of development, but not yet active or recruiting patients.

By submitting an abstract, authors commit to registering to the Congress if selected, unless serious reasons can be invoked (COVID-19 positive test, travel restrictions, severe family problems).

ABSTRACT SELECTION NOTIFICATION

The presenting author will receive the result of the review and the Scientific Committee’s decision on their abstract by email by mid-July 2023.

PRESENTING AUTHOR REGISTRATION

Submitting an abstract for presentation at ESSO 42 does not constitute registration for the congress. Abstract presenters must register to attend the ESSO 42 Congress.

The presenting author of an accepted abstract will be allowed to register at an early rate. Accepted abstracts will only be published in the Congress publications if the presenting author is registered and full payment has been received. Furthermore, the abstract must be presented in person by the author or a co-author at the Congress.

If the presenting author of an accepted abstract is not registered (including full payment received) by 23 August 2023, the abstract will be withdrawn.

PRESENTING AUTHOR REPLACEMENT

If the presenting author of a selected abstract cannot attend, they should assign a replacement and immediately inform the ESSO 42 Secretariat. at abstracts@esso42.org.

注册费：

◆ 参会对象：医生、医院科室主任/副主任、住院医师、医院管理者、医护人员以及从事该领域研究的科学家、研究人员、医药企业代表等等。